What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Cytokine
His primary areas of study are Immunology, Interleukin 6, Internal medicine, Cytokine and Gastroenterology.
His work on Antibody, Acute-phase protein and Host defence as part of general Immunology study is frequently connected to Allergic airway inflammation, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His Interleukin 6 research is multidisciplinary, incorporating perspectives in Hypergammaglobulinemia, T cell and Pathogenesis, Pathology.
Internal medicine is a component of his Rheumatoid arthritis and Arthritis studies.
His Cytokine research incorporates elements of Endocrinology and STAT protein.
His Gastroenterology research includes elements of Pharmacokinetics, Placebo and Adverse effect.
His most cited work include:
- Structure and function of a new STAT-induced STAT inhibitor (1185 citations)
- Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. (1072 citations)
- Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease (743 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Immunology, Interleukin 6, Internal medicine, Cytokine and Molecular biology.
His work in Interleukin 6 addresses issues such as Acute-phase protein, which are connected to fields such as Serum amyloid A.
His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with problems in Adverse effect.
His research in Cytokine intersects with topics in Chemokine, STAT3 and Tumor necrosis factor alpha.
His study on Molecular biology also encompasses disciplines like
- B cell which connect with Cell culture,
- T cell that connect with fields like Antigen and Cytotoxic T cell.
His work deals with themes such as Receptor and Interleukin-6 receptor, which intersect with Antibody.
He most often published in these fields:
- Immunology (46.24%)
- Interleukin 6 (43.01%)
- Internal medicine (28.49%)
What were the highlights of his more recent work (between 2012-2020)?
- Tocilizumab (12.90%)
- Internal medicine (28.49%)
- Rheumatoid arthritis (16.13%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Tocilizumab, Internal medicine, Rheumatoid arthritis, Immunology and Interleukin 6.
His studies in Tocilizumab integrate themes in fields like Antibody, Methotrexate and Pharmacology.
He has included themes like Inflammation, Proinflammatory cytokine and Tumor necrosis factor alpha in his Rheumatoid arthritis study.
His work carried out in the field of Proinflammatory cytokine brings together such families of science as Endocrinology and Cytokine.
His work on Pathogenesis, Arthritis and Hepcidin as part of general Immunology research is often related to Pyrin domain, thus linking different fields of science.
Kazuyuki Yoshizaki undertakes multidisciplinary studies into Interleukin 6 and Sarilumab in his work.
Between 2012 and 2020, his most popular works were:
- International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease (150 citations)
- Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. (79 citations)
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease (76 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Cancer
Kazuyuki Yoshizaki focuses on Tocilizumab, Immunology, Rheumatoid arthritis, Interleukin 6 and Castleman disease.
Internal medicine covers Kazuyuki Yoshizaki research in Tocilizumab.
He studies Internal medicine, focusing on Arthritis in particular.
The study incorporates disciplines such as Tumor necrosis factor alpha, Pharmacokinetics, Pharmacodynamics, Methotrexate and Randomized controlled trial in addition to Rheumatoid arthritis.
His Interleukin 6 study combines topics from a wide range of disciplines, such as Plasma cell, Hepcidin and Pathogenesis.
His research in Castleman disease tackles topics such as Siltuximab which are related to areas like Intensive care medicine, Combination chemotherapy, Erythrocyte sedimentation rate, Hepatosplenomegaly and Plasmacytosis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
